Moreover, in current studies, FAP TRT seemed well tolerated, which corroborates with FDA-approved TRT in patients with neuro-endocrine tumors ([177Lu]Lu-DOTATE) and castration-resistant prostate cancer ([177Lu]Lu-PSMA). Here, FOLH1 is linked to prostate carcinoma.